Abstract
Low molecular weight heparin (LMWH) is used in orthopaedic surgery largely for prophylaxis of venous thromboembolism (VTE). The purpose of this study was to review the available evidence to better define its role. The most recent American College of Chest Physicians Evidence-Based Practice guidelines for the most current recommendations for the application of LMWH to orthopaedic surgery are reviewed. A systematic review of the literature was undertaken using MEDLINE database and manual searches. The terms low molecular weight heparin, orthopaedic procedures, venous thromboembolism, and thromboprophylaxis were used as keywords. A total of 34 studies were identified, including prospective, randomised controlled clinical studies comparing LMWH with other treatment methods in orthopaedic surgery patients, meta-analysis and health economic related studies. There is clear supporting evidence for the application of LMWH for DVT prophylaxis in orthopaedic surgery. Although newer agents such as oral thrombin inhibitors are being developed for DVT prophylaxis, it will take some time to adequately assess the clinical efficacy, safety, and costeffectiveness of these newer agents. Whether these agents will ultimately supplant the widespread application of LMWH to orthopaedic surgery remains to be seen.
Keywords: Orthopaedic surgery, thromboprophylaxis, venous thromboembolism, low molecular weight heparin, unfractionated heparin (UFH), heparinase, anti-Xa, anti-IIa activity, LMWH, MEDLINE (OVID), lower extremity injury, pelvic, acetabular frac-tures, major trauma, THA, TKA, retrospective cohort study, multicentre trial, 4 meta-analyses, health economic-related, thrombocytopenia, placebo, unfractionated heparins, dextran, UFH, fatal pulmonary, proximal DVT, warfarin, low-dose hepa-rin, deep vein thrombosis, LMWH prophylaxis, NHS EED, enoxaparin led, VTE, ACCP, fondaparinux, normalised ratio, PE secondary, thrombosis, prophy-lactic, war-farin
Current Vascular Pharmacology
Title: Low Molecular Weight Heparin: Current Evidence for Its Application in Orthopaedic Surgery
Volume: 9 Issue: 1
Author(s): Bharati S. Kalyani and Craig S. Roberts
Affiliation:
Keywords: Orthopaedic surgery, thromboprophylaxis, venous thromboembolism, low molecular weight heparin, unfractionated heparin (UFH), heparinase, anti-Xa, anti-IIa activity, LMWH, MEDLINE (OVID), lower extremity injury, pelvic, acetabular frac-tures, major trauma, THA, TKA, retrospective cohort study, multicentre trial, 4 meta-analyses, health economic-related, thrombocytopenia, placebo, unfractionated heparins, dextran, UFH, fatal pulmonary, proximal DVT, warfarin, low-dose hepa-rin, deep vein thrombosis, LMWH prophylaxis, NHS EED, enoxaparin led, VTE, ACCP, fondaparinux, normalised ratio, PE secondary, thrombosis, prophy-lactic, war-farin
Abstract: Low molecular weight heparin (LMWH) is used in orthopaedic surgery largely for prophylaxis of venous thromboembolism (VTE). The purpose of this study was to review the available evidence to better define its role. The most recent American College of Chest Physicians Evidence-Based Practice guidelines for the most current recommendations for the application of LMWH to orthopaedic surgery are reviewed. A systematic review of the literature was undertaken using MEDLINE database and manual searches. The terms low molecular weight heparin, orthopaedic procedures, venous thromboembolism, and thromboprophylaxis were used as keywords. A total of 34 studies were identified, including prospective, randomised controlled clinical studies comparing LMWH with other treatment methods in orthopaedic surgery patients, meta-analysis and health economic related studies. There is clear supporting evidence for the application of LMWH for DVT prophylaxis in orthopaedic surgery. Although newer agents such as oral thrombin inhibitors are being developed for DVT prophylaxis, it will take some time to adequately assess the clinical efficacy, safety, and costeffectiveness of these newer agents. Whether these agents will ultimately supplant the widespread application of LMWH to orthopaedic surgery remains to be seen.
Export Options
About this article
Cite this article as:
S. Kalyani Bharati and S. Roberts Craig, Low Molecular Weight Heparin: Current Evidence for Its Application in Orthopaedic Surgery, Current Vascular Pharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157016111793744661
DOI https://dx.doi.org/10.2174/157016111793744661 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting of Antioxidant and Anti-Thrombotic Drugs to Endothelial Cell Adhesion Molecules
Current Pharmaceutical Design Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction
Current Drug Safety Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews Homocystinuric Patient with Deficient CBS Activity: Pyridoxine Efficacy and Toxicity?
Letters in Drug Design & Discovery Editorial [Hot topic: Antithrombotic Therapy in Cardiovascular and Haematological Diseases: New Perspectives (Executive Editors: Sergio Siragusa, Giuseppe Barbaro and Giovanni Fazio)]
Current Pharmaceutical Design Emerging Anticoagulant Therapies for Atrial Fibrillation: New Options, New Challenges
Current Medicinal Chemistry Primary and Secondary Stroke Prevention with Antiplatelet Drugs
Current Pharmaceutical Design Increased Neutrophil-to-lymphocyte Ratios are Associated with Greater Risk of Hemorrhagic Transformation in Patients with Acute Ischemic Stroke
Current Neurovascular Research Prostacyclin, Atherothrombosis and Diabetes Mellitus: Physiologic and Clinical Considerations
Current Molecular Medicine Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets The Discovery of the Factor Xa Inhibitor Otamixaban: From Lead Identification to Clinical Development
Current Medicinal Chemistry Cardiac Biomarkers in Stroke, Alzheimer’s Disease, and Other Dementia. Are They of Use? A Brief Overview of Data from Recent Investigations
CNS & Neurological Disorders - Drug Targets The Effects of Drugs Used in Anaesthesia on Platelet Membrane Receptors and on Platelet Function
Current Drug Targets Endovascular Therapeutic Embolisation: An Overview of Occluding Agents and their Effects on Embolised Tissues
Current Vascular Pharmacology Subject Index To Volume 12
Current Pharmaceutical Design Polysulfated/Sulfonated Compounds for the Development of Drugs at the Crossroad of Viral Infection and Oncogenesis
Current Pharmaceutical Design Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers
Recent Patents on Anti-Infective Drug Discovery Biochemical and Pharmacologic Heterogeneity in Low Molecular Weight Heparins. Impact on the Therapeutic Profile
Current Pharmaceutical Design Peptides Derived from Platelet Non-integrin Collagen-receptors or Types I and III Collagen Inhibit Collagen-Platelet Interaction
Cardiovascular & Hematological Disorders-Drug Targets Effects of Lipid-Lowering Agents on Inflammation, Haemostasis and Blood Pressure
Current Pharmaceutical Design